Results 101 to 110 of about 5,902,779 (250)

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

The effect of perceived busyness on nostalgic consumption intention: based on compensatory control theory. [PDF]

Front Psychol
Huang E, Zhu X, Yao F, Zhao T.
europepmc   +1 more source

Towards a network control theory of electroconvulsive therapy response. [PDF]

PNAS Nexus, 2023
Hahn T, Jamalabadi H, Nozari E, Winter NR, Ernsting J, Gruber M, Mauritz MJ, Grumbach P, Fisch L, Leenings R, Sarink K, Blanke J, Vennekate LK, Emden D, Opel N, Grotegerd D, Enneking V, Meinert S, Borgers T, Klug M, Leehr EJ, Dohm K, Heindel W, Gross J, Dannlowski U, Redlich R, Repple J.   +26 more
europepmc   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source

Optimal control theory as a method for designing multidrug adaptive therapy regimens. [PDF]

NPJ Syst Biol Appl
Widdershins A, Hansen E, Read A, Hohl R.
europepmc   +1 more source

Oromotor Nonverbal Performance and Speech Motor Control: Theory and Review of Empirical Evidence. [PDF]

Brain Sci, 2023
Weismer G.
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

The relationship between sense of control and system-justifying belief: an examination from the compensatory control theory. [PDF]

BMC Psychol
Luo P, Jin W, Geng Y.
europepmc   +1 more source

Pandemic control - do's and don'ts from a control theory perspective. [PDF]

World J Methodol, 2022
Tomov L, Miteva D, Sekulovski M, Batselova H, Velikova T.   +4 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source